Abstract
Therapeutic oncolytic viruses (virotherapeutics) constitute a novel class of targeted anticancer agents that have unique mechanisms of action compared with other cancer therapeutics. The development of virotherapeutics has evolved from the use of in vitro-passaged strains (first generation), to genetically engineered selectivity-enhanced viruses (second generation) and finally to genetically engineered transgene-expressing 'armed' oncolytic viruses (third generation). Descriptions of cancer remissions following virus infections date back to a century ago. Initial patient treatment publications, written up to 50 years ago, consisted of case reports or case series of treatment with first-generation, non-engineered viruses. Over the past decade, hundreds of patients with cancer have been treated on prospectively designed clinical trials (including phase III), evaluating over 10 different agents, inlcluding engineered second-generation and third-generation viruses. This Review summarizes and interprets the data from clinical reports over the last century, including safety, efficacy and biological end points (viral and immunologic). Systemic safety and efficiacy has been clearly demonstrated with some virotherapeutics. The implications of these data for future virotherapy development are discussed.
Key Points
-
Oncolytic viruses can be safely administered into patients via different routes; systemic efficacy has been demonstrated with some virotherapeutics
-
Virus replication can be demonstrated in vivo after local administration, and with some viruses after intravenous administration
-
There is no cross-resistance of oncolytic viruses with standard therapeutics; response to virotherapy is virus species and tumor-specific
-
Virotherapy enhances or synergizes with chemotherapy and radiotherapy
-
Modern technologies have allowed the incorporation of transgenes into oncolytic viruses for therapeutic or monitoring purposes
-
Neutralizing antibodies do not affect efficacy with local and local-regional administration, and the induction of immune reactions may have a role in antitumoral efficacy of viruses
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dock G (1904) Influence of complicating diseases upon leukemia. AM J Med Sci 127: 563–592
Bierman HR et al. (1953) Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia. Cancer 6: 591–605
Pasquinucci G (1971) Possible effect of measles on leukaemia. Lancet 1: 136
Bluming AZ and Ziegler JL (1971) Regression of Burkitt's lymphoma in association with measles infection. Lancet 2: 105–106
Taqi AM et al. (1981) Regression of Hodgkin's disease after measles. Lancet 1: 1112
Csatary LK (1971) Viruses in the treatment of cancer. Lancet 2: 825
DePace NG (1912) Sulla Scomparsa di un enorme cancro begetante del callo dell'utero senza cura chirurgica [Italian]. Ginecolgia 9: 82
Hansen RM and Libnoch JA (1978) Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med 138: 1137–1138
Greentree LB (1983) Hodgkin's disease: therapeutic role of measles vaccine. Am J Med 75: 928
Schattner A (1984) Therapeutic role of measles vaccine in Hodgkin's disease. Lancet 1: 171
Southam CM and Moore AE (1951) West Nile, Ilheus, and Bunyamwera virus infections in man. Am J Trop Med Hyg 31: 724–741
Huebner RJ et al. (1956) Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9: 1211–1218
Asada T (1974) Treatment of human cancer with mumps virus. Cancer 34: 1907–1928
Shimizu Y et al. (1988) Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus. Cancer Detect Prev 12: 487–495
Milton GW and Brown MM (1966) The limited role of attenuated smallpox virus in the management of advanced malignant melanoma. Aust N Z J Surg 35: 286–290
Hunter-Craig I et al. (1970) Use of vaccinia virus in the treatment of metastatic malignant melanoma. BMJ 2: 512–515
Arakawa S Jr et al. (1987) Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma: report on two cases. J Cancer Res Clin Oncol 113: 95–98
Gomella LG et al. (2001) Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 166: 1291–1295
Roenigk HH Jr et al. (1974) Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 109: 668–673
Kawa A and Arakawa S (1987) The effect of attenuated vaccinia virus AS strain on multiple myeloma: a case report. Jpn J Exp Med 57: 79–81
Mastrangelo MJ et al. (1995) A pilot study demonstrating the feasability of using intratumoral vaccinia injections as a vector for gene transfer. Vaccine Res 4: 55–69
Everall JD et al. (1975) Treatment of primary melanoma by intralesional vaccinia before excision. Lancet 2: 583–586
Southam CM and Moore AE (1952) Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer 5: 1025–1034
Okuno Y et al. (1978) Studies on the use of mumps virus for treatment of human cancer. Biken J 21: 37–49
Toolan HW et al. (1965) H-1 Virus viremia in the human. Proc Soc Exp Biol Med 119: 711–715
Wheelock EF and Dingle JH (1964) Observations on the repeated administration of viruses to a patient with acute leukemia: a preliminary report. N Engl J Med 271: 645–651
Cassel WA and Garrett RE (1965) Newcastle Disease Virus as an antineoplastic agent. Cancer 18: 863–868
Csatary LK et al. (1993) Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17: 619–627
Csatary LK and Bakacs T (1999) Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 281: 1588–1589
Csatary LK et al. (2004) MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neuro-oncol 67: 83–93
Kirn D et al. (2001) Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7: 781–787
Pecora AL et al. (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20: 2251–2266
Lorence RM et al. (2003) Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 5: 618–624
Freeman AI et al. (2006) Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13: 221–228
Morris DG et al. (2002) A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies [abstract # 92]. Proc Am Soc Clin Oncol 21: a24
Kirn D (2001) Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 8: 89–98
Morley S et al. (2004) The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res 10: 4357–4362
Mulvihill S et al. (2001) Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 8: 308–315
Nemunaitis J et al. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 60: 6359–6366
Ganly I et al. (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798–806
Nemunaitis J et al. (2001) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19: 289–298
Chiocca EA et al. (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10: 958–966
Vasey PA et al. (2002) Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 20: 1562–1569
Makower D et al. (2003) Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 9: 693–702
Reid T et al. (2002) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62: 6070–6079
Habib NA et al. (2001) E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 12: 219–226
Habib N et al. (2002) Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 9: 254–259
Nemunaitis J et al. (2001) Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8: 746–759
Hamid O et al. (2003) Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 21: 1498–1504
Khuri FR et al. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879–885
Yuan ZY et al. (2003) Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer [Chinese]. Ai Zheng 22: 310–313
Lu W et al. (2004) Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 10: 3634–3638
Xia ZJ et al. (2004) Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus [Chinese]. Ai Zheng 23: 1666–1670
DeWeese TL et al. (2001) A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61: 7464–7472
Small EJ et al. (2006) A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14: 107–117
Markert JM et al. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867–874
Kemeny M et al. (2006) Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17: 1214–1224
Mastrangelo MJ et al. (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409–422
Hu JC et al. (2006) A phase I clinical trial with OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12: 6737–6747
Freytag SO et al. (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968–4976
Freytag SO et al. (2003) Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497–7506
Laurie SA et al. (2006) A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 12: 2555–2562
Hotte SJ et al. (2003) Slow intravenous infusion of PV701, an oncolytic virus: final results of a phase I study [abstract # 3037]. Proc Am Soc Clin Oncol 22: s14s
Horstmann E et al. (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352: 895–904
Hecht JR et al. (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 9: 555–561
Galanis E et al. (2005) Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 12: 437–445
Reid T et al. (2001) Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 8: 1618–1626
Nemunaitis J et al. (2003) Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 10: 341–352
Wein LM et al. (2003) Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 63: 1317–1324
Rampling R et al. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859–866
Papanastassiou V et al. (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9: 398–406
Harrow S et al. (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11: 1648–1658
MacKie RM et al. (2001) Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357: 525–526
Gross (1971) Measles and leukaemia. Lancet 1: 397–398
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D Kirn has declared he is has ownership in and employment by Jennerex Biotherapeutics ULC, a company developing development oncolytic viruses for cancer patients. The other authors declared they have no competing interests.
Rights and permissions
About this article
Cite this article
Liu, TC., Galanis, E. & Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Rev Clin Oncol 4, 101–117 (2007). https://doi.org/10.1038/ncponc0736
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0736
This article is cited by
-
Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment
Cell Communication and Signaling (2023)
-
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment
Molecular Cancer (2023)
-
A bibliometric review of oncolytic virus research as a novel approach for cancer therapy
Virology Journal (2021)
-
Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer
Cancer Gene Therapy (2021)
-
Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
Scientific Reports (2021)